Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

 

 
Drawing on brainstorming sessions and focus groups that were conducted in the summer of 2011, this paper highlights the experiences of NPA members in their own words.
Original research | 2013
Policy/Regulatory, Wrap-around services, Safer supply, Decriminalization/legalization, Equity, Advocacy, About PWUD, Social services, Outcomes, Peer/PWLLE program involvement, Social benefits, Stigma
Archived webinar | various
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Injecting drugs
Archived webinar | 2020
Clinical guidance, Harm reduction, Safer supply, About pharmacists, About prescribers, Housing
The current study aimed to compare the cost-effectiveness of hydromorphone directly with diacetylmorphine and indirectly with methadone maintenance treatment.
Original research | 2018
Evidence base, Safer supply, Crime, Substitution/OAT
PO diversion is widely regarded as a driver of OD mortality.
Original research | 2021
Harm reduction, Safer supply, About PWUD, Barriers and enablers, Poverty, Diversion
Guidelines | 2017
Clinical guidance, Evidence base, Policy/Regulatory, About prescribers
Guidelines | 2023
Clinical guidance, Policy/Regulatory, About prescribers
We discuss accumulated evidence (Box 1) on social interventions and provide an overview of common primary care–based interventions (Table 1), highlighting their strengths, limitations and feasibility
Lit review | 2021
Clinical guidance, Wrap-around services, Equity, About prescribers, Social services
What is the clinical effectiveness of injectable opioid agonist treatment for patients with opioid dependence?
Lit review | 2020
Mortality, Evidence base, Outcomes, Social benefits
To describe 4-year treatment retention and treatment response among chronic, treatment-resistant heroin-dependent patients offered long-term heroin-assisted treatment (HAT) in the Netherlands.
Original research | 2009
Evidence base, Harm reduction, Safer supply, About prescribers, Outcomes, Illegal drugs
Created in collaboration with peers and providers
Guidelines | 2018
About prescribers, About PWUD, Workplace, Peer/PWLLE program involvement
Commentary | 2021
Policy/Regulatory, Decriminalization/legalization, About prescribers, Hallucinogens/psychedelics
Handout | 2021
Safer supply, Illegal drugs, Diversion

BC safe suply interim guidance for safe supply/COVID-19 risk mitigation during the pandemic

Guidelines | 2022
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Rural/remote, Substitution/OAT, Carries/take-home doses
Guidelines | 2017
Clinical guidance, Policy/Regulatory, About prescribers, SCS/OPS
The cost-effectiveness of Canada's only supervised injection facility has not been rigorously evaluated.
Original research | 2008
Evidence base, Advocacy, Illegal drugs, Social benefits, SCS/OPS
This study estimated retention in buprenorphine and methadone treatment and its relationship with person, treatment and prescriber characteristics.
Original research | 2021
About prescribers, Substitution/OAT
WHO observed that the social fallout from COVID-19 hits women even harder (economic insecurity, single parenthood, violence, barriers to accessing services, etc.).
Lit review | 2020
Equity, Sex/Gender
Commentary | 2021
Mortality, Policy/Regulatory, Safer supply, Equity, Barriers and enablers, Housing, Rural/remote, Small/medium cities, Stigma

Affiner votre recherche

Mots clés
Format
Région